Patents by Inventor Paul G. Lysko

Paul G. Lysko has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds
    Publication number: 20020019432
    Abstract: A new antioxidant neuroprotective use of and method of treatment using, selected hydroxycarbazole compounds or a pharmaceutically acceptable salt thereof. The new use of, and method of treatment using, the antioxidant compounds prevents oxidative tissue damage to organs, particularly the central nervous system including the brain in mammals afflicted with disease-induced ischemic trauma, particularly stroke.
    Type: Application
    Filed: September 20, 2001
    Publication date: February 14, 2002
    Applicant: SmithKline Beecham Corporation
    Inventors: Frank C. Barone, Giora Feuerstein, Tian-Li Yue, Paul G. Lysko, Hung-Yuan Cheng
  • Antioxidant neuroprotective use of, and method of treatment using, hydroxycarbazole compounds
    Publication number: 20010011099
    Abstract: A new antioxidant neuroprotective use of and method of treatment using, selected hydroxycarbazole compounds or a pharmaceutically acceptable salt thereof. The new use of, and method of treatment using, the antioxidant compounds prevents oxidative tissue damage to organs, particularly the central nervous system including the brain in mammals afflicted with disease-induced ischemic trauma, particularly stroke.
    Type: Application
    Filed: March 13, 2001
    Publication date: August 2, 2001
    Applicant: SmithKline Beecham Corporation
    Inventors: Frank C. Barone, Giora Feuerstein, Tian-Li Yue, Paul G. Lysko, Hung-Yuan Cheng
  • Macrophage scavenger receptor antagonists for use in the treatment of cardiovascular diseases
    Patent number: 6255298
    Abstract: Salicylanilide derivatives which are macrophagescavenger receptor antagonists are provided. Methods of treating cardiovascular disease comprising administration of the present compounds are also provided. The present compounds inhibit lipid accumulation within macrophage-derived foam cells.
    Type: Grant
    Filed: January 28, 2000
    Date of Patent: July 3, 2001
    Assignee: SmithKline Beecham Corporation
    Inventors: Paul G. Lysko, Joseph Weinstock
  • Attachment enhanced 293 cells
    Patent number: 5863798
    Abstract: Attachment enhanced human embryonic kidney cells, 293, are provided. These cells have been modified to contain a selected mammalian scavenger gene, which has been found to improve the ability of these cells to attach in culture. The improved cells of the invention are useful in assays in which the unmodified 293 cells could be used.
    Type: Grant
    Filed: October 9, 1997
    Date of Patent: January 26, 1999
    Assignee: SmithKline Beecham Corporation
    Inventors: Paul G. Lysko, Nabil A. Elshourbagy, Mary E. Brawner
  • Attachment enhanced 293 cells
    Patent number: 5683903
    Abstract: Attachment enhanced human embryonic kidney cells, 293, are provided. These cells have been modified to contain a selected mammalian scavenger gene, which has been found to improve the ability of these cells to attach in culture. The improved cells of the invention are useful in assays in which the unmodified 293 cells could be used.
    Type: Grant
    Filed: May 30, 1995
    Date of Patent: November 4, 1997
    Assignee: SmithKline Beecham Corporation
    Inventors: Paul G. Lysko, Nabil A. Elshourbagy, Mary E. Brawner